Key Takeaways Mirum reported Q3 earnings of 5 cents per share, beating expectations of a 10-cent loss.Q3 revenues rose 47.1% year over year to $133 million, driven by Livmarli and bile acid product growth.MIRM tightened its 2025 revenue outlook to$500-$510 million from its earlier$490-$510 million range.Mirum Pharmaceuticals (MIRM) reported earnings of 5 cents per share for the third quarter of 2025 against the Zacks Consensus Estimate of a loss of 10 cents. The company had incurred a loss of 30 cents per ...